PsiOxus partners with Parker Institute on gene therapy for solid tumors
PsiOxus Therapeutics announced that it is partnering with the Parker Institute for Cancer Immunotherapy, founded by former Facebook President Sean Parker, to investigate a virus-based gene therapy technology in treating solid tumors. PsiOxus’ platform, called T-SIGn, uses a viral vector to deliver therapeutic genes to tumors. The technology is designed to turn tumor cells into “drug factories” that churn out immune-boosting compounds, the company said in a statement. PsiOxus and the Parker Institute will work together to test different combinations of viruses and genes in preclinical models.